Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: October 2008
-
By Christopher P. Singer — In a Notice published in the Federal Register on October 9, 2008, the U.S. Patent and Trademark Office announced the names of persons that have been appointed to the Performance Review Board. Among the twelve familiar names constituting the Board, Margaret J. A. Peterlin (Under Secretary of Commerce…
-
By Kevin E. Noonan — As Patent Docs has reported (see Part I and Part II), last week District Court Judge William G. Young (D. Mass) issued a 150-page decision on post-trial motions and a permanent injunction, and provided his rationale for a number of pretrial summary judgment motion decisions, in Amgen Inc.…
-
By Richard Belzer — The U.S. Patent and Trademark Office (PTO) today published a notice in the Federal Register inviting public comments on paperwork burdens associated with the changes in the procedural requirements for ex parte appeals (73 Fed. Reg. 32937-32977, June 10, 2008). This notice arises under the Paperwork Reduction Act (44…
-
By Kevin E. Noonan — On October 2nd, District Court Judge William G. Young (D. Mass) issued a decision on post-trial motions and a permanent injunction in Amgen Inc. v. Hoffmann-LaRoche, Amgen’s patent infringement suit over Roche’s Mircera® drug product. In a 150-page opinion, Judge Young handed Amgen nothing less than a complete…
-
By Donald Zuhn — Last Friday, the Federal Circuit affirmed the determination by the District Court for the District of Delaware that U.S. Patent No. 5,236,940 does not qualify as an enabling prior art reference, and therefore, does not anticipate claims 1-5 of U.S. Patent No. 5,527,814. The ‘814 patent, which is owned…
-
By Kevin E. Noonan — On October 2nd, District Court Judge William G. Young (D. Mass) issued a decision on post-trial motions and a permanent injunction in Amgen Inc. v. Hoffmann-LaRoche, Amgen’s patent infringement suit over Roche’s Mircera® drug product. In a 150-page opinion, Judge Young handed Amgen nothing less than a complete…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Proctor & Gamble Co. et al. v. Teva Pharmaceuticals USA Inc.1:08-cv-00627; filed September 26, 2009 in the District Court of Delaware Infringement…
-
October 6-7, 2008 – Patent Litigation 2008 (Practising Law Institute) – McLean, VA October 7-8, 2008 – Global Patent Litigation*** (American Conference Institute) – New York, NY October 15, 2008 – Developments in Pharmaceutical and Biotech Patent Law (Practising Law Institute) – San Francisco, CA October 15-16, 2008 – Pharmaceutical Congress on Paragraph IV Disputes***…
-
American Conference Institute (ACI) will be holding its 6th National Conference on Pharma/Biotech IP Due Diligence from January 28-29, 2009 in New York. The conference will allow attendees to: • Define the company’s business goals before you begin a due diligence review;• Navigate the dynamic labyrinth of cases that can impact the company’s IP rights;•…
-
By Kevin E. Noonan — The Federal Circuit’s inequitable conduct jurisprudence has appeared for some time to be unduly fact- and panel-dependent, straying in the opinion of at least Judge Rader from the principle enunciated in the Court’s en banc decision in Kingsdown Medical Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867 (Fed.…
Patent Docs 